echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Annual report disclosure season: A number of pharmaceutical equipment companies have obtained performance forecasts from securities companies and are expected to see strong performance growth

    Annual report disclosure season: A number of pharmaceutical equipment companies have obtained performance forecasts from securities companies and are expected to see strong performance growth

    • Last Update: 2022-04-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    It is the annual report disclosure season recently, and many listed pharmaceutical machine companies have disclosed their 2021 performance reports
    .
    For example, Canaan Technology, the company will achieve a net profit of 76.
    1539 million in 2021, a year-on-year increase of 12.
    15%, mainly due to the steady increase in project orders during the reporting period

    .
    At present, Chutian Technology, Tofflon and other leading pharmaceutical equipment companies have not disclosed their annual reports, but they have obtained performance forecasts from securities companies

    .
    Overall, brokerages generally expect strong performance growth for these companies in 2021

    .
    Pharmaceutical Equipment (Source: Pharmaceutical Network) Tofflon: Predicted net profit of 796 million yuan The data shows that as of March 16, 2022, a total of 7 institutions have made predictions on Tofflon's 2021 annual performance, including Industrial Securities, Guosheng Securities, China Merchants Securities, Zheshang Securities, CITIC Construction Investment, Essence Securities, Guohai Securities; Tofflon’s net profit is forecast to be 796 million yuan in 2021, a year-on-year increase of 71.
    68%

    .
    Among them, 4 institutions "buy", 1 institution "prudently increases", 1 institution "strongly recommends", and 1 institution "increases"

    .
    The target price is predicted to be 48.
    57 yuan

    .
    Judging from the forecast values ​​of the seven institutions, Guohai Securities predicts that Tofflon will have a net profit of 738 million yuan in 2021, while Industrial Securities predicts that the company will receive a net profit of 1.
    036 billion yuan

    .
    In addition, four institutions including China Securities Construction Investment, Zheshang Securities, China Merchants Securities, and Guosheng Securities also predict that the company's net profit in 2021 will exceed 1 billion yuan

    .
    The report released by Industrial Securities on March 2 pointed out that recently, Tofflon released the "2022 A-share issuance plan to specific objects".
    The total amount of funds raised this time does not exceed 3.
    20 billion yuan, which is planned to be used for the trial production of the biopharmaceutical equipment industry.
    Center project, Jiangsu biomedical equipment industrialization base project, Hangzhou life science industrialization base project, supplementary working capital

    .
    The agency believes that the company's investment projects are in line with the booming market trend of biological front-end equipment and consumables and the company's established strategy, which can enhance the company's core competitiveness and facilitate the sustainable development of high-growth business segments.

    .
    In this regard, the profit forecast has been adjusted, and the company's revenue is expected to reach 4.
    190 billion yuan in 2021, with a growth rate of 54.
    8%

    .
    Without considering the additional issuance, the company's net profit attributable to the parent company is expected to reach 822 million yuan in 2021

    .
    Chutian Technology: Predicted net profit of 530 million yuan As of March 16, 2022, a total of 6 institutions within 6 months have made predictions on the 2021 annual performance of Chutian Technology, namely GF Securities, Southwest Securities, Zheshang Securities, Guoxin Securities, etc.
    ; it is predicted that the net profit in 2021 will be 530 million yuan, a year-on-year increase of 164.
    53%

    .
    Among them, 5 institutions "buy" and 1 institution "increase"

    .
    The target price forecast is 35.
    00 yuan

    .
    Most brokerages predict that the net profit of Chutian Technology in 2021 will be more than 500 million yuan

    .
    Among them, GF Securities recently released a report saying that Chutian Technology is a well-tested domestic pharmaceutical equipment giant in China.
    In addition, the downstream demand for biopharmaceuticals is strong, domestic substitution is accelerated, and capacity expansion has brought new growth in performance; the downstream demand for bioengineering is strong, The company's performance is released with the expansion of production capacity; the company continues to promote the internationalization strategy to achieve export substitution, and the planned production capacity is expected to accelerate the growth of overseas performance

    .
    It is expected that the company's net profit attributable to the parent company in 2021 will be 543 million yuan, with a growth rate of 170.
    9%

    .
    Conclusion Judging from the reports disclosed by many securities companies, most securities companies are optimistic about the domestic alternative space of the pharmaceutical equipment industry in the context of the rapid development of the biopharmaceutical industry

    .
    Relatively speaking, leading companies have more advantages in resources, R&D, and technology.
    As the pharmaceutical equipment industry ushered in a new round of opportunities, it is expected that the pharmaceutical machine giants represented by Chutian Technology and Tofflon will benefit significantly

    .
    At present, these companies are all taking the pulse of the market development trend and actively deploying, such as expanding the talent team internally, increasing investment in innovation and R&D, expanding production capacity, and deploying in the field of biopharmaceuticals.
    Occupy more market share in the future market

    .
    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.